SRR615096
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.483
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.437
- KRAS_SIGNALING_DN+0.430
- ANGIOGENESIS+0.390
- COAGULATION+0.366
- INFLAMMATORY_RESPONSE+0.347
- APICAL_SURFACE+0.311
- APICAL_JUNCTION+0.300
- ESTROGEN_RESPONSE_EARLY+0.283
- KRAS_SIGNALING_UP+0.259
Top 10 suppressed
- MYC_TARGETS_V1-0.672
- OXIDATIVE_PHOSPHORYLATION-0.625
- DNA_REPAIR-0.550
- PROTEIN_SECRETION-0.519
- MTORC1_SIGNALING-0.515
- UNFOLDED_PROTEIN_RESPONSE-0.509
- MYC_TARGETS_V2-0.497
- E2F_TARGETS-0.436
- G2M_CHECKPOINT-0.414
- PI3K_AKT_MTOR_SIGNALING-0.395
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1362464 | GTEX | — | 0.960 |
| 2 | SRR1396078 | GTEX | — | 0.948 |
| 3 | SRR1457221 | GTEX | — | 0.947 |
| 4 | SRR598276 | GTEX | — | 0.942 |
| 5 | SRR1330061 | GTEX | — | 0.937 |
| 6 | SRR820292 | GTEX | — | 0.935 |
| 7 | SRR1331289 | GTEX | — | 0.935 |
| 8 | SRR1417070 | GTEX | — | 0.935 |
| 9 | SRR1375616 | GTEX | — | 0.933 |
| 10 | SRR598638 | GTEX | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.483 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.437 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.430 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| COAGULATION | 0.366 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.347 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.311 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.283 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.259 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.242 | Idelalisib | — uncovered |
| COMPLEMENT | 0.219 | Inavolisib | — uncovered |
| HYPOXIA | 0.201 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.198 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.165 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.153 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.136 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.132 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.117 | Idelalisib | — uncovered |